Ziprasidone- and lithium-induced neuroleptic malignant syndrome

Annals of Pharmacotherapy

Volumn 40, Issue 1, 2006, Pages 139-142

  Borovicka, Mary C ^a,b   Bond, Linda C ^c   Gaughan, Kerri M ^d  

^a UNIVERSITY OF TOLEDO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Louis Stokes Veterans' Affairs Medical Center   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

Lithium; Neuroleptic malignant syndrome; Ziprasidone

Indexed keywords

CREATINE KINASE; DOPAMINE 2 RECEPTOR; LITHIUM; LORAZEPAM; NEUROLEPTIC AGENT; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; AGITATION; ARTICLE; CASE REPORT; DIAPHORESIS; DISEASE EXACERBATION; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; HYPERTHERMIA; HYPOTENSION; LEUKOCYTE COUNT; MALE; MANIA; MENTAL HEALTH; MUSCLE RIGIDITY; MYOGLOBINURIA; NARANJO PROBABILITY SCALE; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; RATING SCALE; RECEPTOR AFFINITY; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SYMPTOMATOLOGY; TACHYCARDIA; TACHYPNEA;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPOTENSION; LITHIUM; MALE; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PIPERAZINES; PSYCHOTIC DISORDERS; THIAZOLES;

EID: 32344433699     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G470     Document Type: Article

References (16)

1. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-45.
2. Addonizio G, Susman VL, Roth SD. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 1987;22:1004-20.
3. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhorn G. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
4. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
5. Gill J, Singh H, Nugent K, Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 2003;23:811-5.
6. Murty RG, Mistry SG, Chacko RC. Neuroleptic malignant syndrome with ziprasidone. J Clin Psychopharmacol 2002;22:624-6.
7. Yang SH, McNeely MJ. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone (letter). Am J Psychiatry 2002;159:1435.
8. Liebold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Therapeut 2004;26:1105-7.
9. Gray NS. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge. Hum Psychopharmacol Clin Exp 2004;19:205-7.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000.
12. Goldman SA. FDA Medwatch report: lithium and neuroleptics in combination: the spectrum of neurotoxicity. Psychopharmacol Bull 1996;32: 299-309.
13. 2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001;158:1714-6.
14. Lee JWL. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499-507.
15. Ananth J. Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate (letter). J Clin Psychiatry 2004;65:724.
16. Berry N, Pradhan S, Sagar R, Gupta SK. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 2003;23:255-9.